15 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
continue to execute on our strategy and advance our pivotal clinical trials of lorundrostat for the treatment of hypertension. Enrollment
424B5
MLYS
Mineralys Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:35pm
position, business strategy, research and development plans, the anticipated timing, costs, design, and conduct of our ongoing and planned preclinical … ;
persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
biopharmaceutical company, from July 2020 to October 2021. Ms. Karydas previously served as Senior Vice President of Corporate Strategy and Financial … Planning & Analysis at Allergan plc, where she oversaw the company’s long-term financial and business strategy, until its acquisition by AbbVie Inc
S-3
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Shelf registration
7:30am
of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design, and conduct of our ongoing … applicable free writing prospectus, including statements regarding our future results of operations and financial position, business strategy, research
8-K
pv55xamaq9e mk0
14 Sep 23
Departure of Directors or Certain Officers
4:11pm
8-K
EX-99.1
iipx0qibis
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
10-Q
lkhq5zc
15 May 23
Quarterly report
5:25pm
DRS/A
wvt66q4lskqhitq4sv
29 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
h23tp0 ux
7 Dec 22
Draft registration statement (amended)
12:00am
DRS
EX-10.9
vsa28hrc5pozsnp
4 Nov 22
Draft registration statement
12:00am
DRS
h8vh6wol02 l0tn0m
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next